PMID- 10650795
OWN - NLM
STAT- MEDLINE
DCOM- 20000222
LR  - 20131121
IS  - 0250-7005 (Print)
IS  - 0250-7005 (Linking)
VI  - 19
IP  - 5C
DP  - 1999 Sep-Oct
TI  - Lung function and serum concentration of tumor necrosis factor-alpha, 
      interleukin-6 and fibronectin in patients treated with ABVD chemotherapy followed 
      by radiotherapy for mediastinal Hodgkin's disease.
PG  - 4475-9
AB  - Mediastinal radiotherapy and polychemotherapy regimens can produce late toxicity 
      leading to pulmonary fibrosis. There is evidence for the involvement of various 
      cytokines in this process. We evaluated lung function in 20 patients with stage 
      I-IIA Hodgkin's disease and submitted to chemotherapy including bleomycin (ABVD) 
      and radiotherapy. Lung function tests were performed before, at the end of 
      treatment and after a median of 12 months from the end of therapy. Tumor necrosis 
      factor-alpha (TNF-alpha), fibronectin and interleukin-6 (IL-6) were determined on 
      serum samples collected at the same time intervals. A modification of tests 
      indicative of a restrictive lung disease was observed at end of treatment, 
      whereas a persistent decline of transfer lung factor for carbon monoxide (DLCO) 
      was documented. TNF-alpha constantly decreased, fibronectin increased and IL-6 
      showed a decline after treatment and a rise during the follow-up but the 
      differences were not statistically significant. No significant correlations were 
      observed between changes of lung function tests and serum cytokine concentration. 
      CONCLUSIONS: This lack of correlation could be due to: a) incorrect selection of 
      serum collection time, or b) to the fact that cytokine plasma concentration does 
      not reflect events occurring in the alveolar phase.
FAU - Villani, F
AU  - Villani F
AD  - Divisione di Cardiologia e Fisiopatologia Respiratoria, Istituto Nazionale per lo 
      Studio e la Cura dei Tumori, Milan, Italy.
FAU - Dell'Oca, I
AU  - Dell'Oca I
FAU - De Maria, P
AU  - De Maria P
FAU - Viola, G
AU  - Viola G
FAU - Di Russo, A
AU  - Di Russo A
FAU - Viviani, S
AU  - Viviani S
FAU - Bonfante, V
AU  - Bonfante V
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Fibronectins)
RN  - 0 (Interleukin-6)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 11056-06-7 (Bleomycin)
RN  - 5V9KLZ54CY (Vinblastine)
RN  - 7GR28W0FJI (Dacarbazine)
RN  - 80168379AG (Doxorubicin)
RN  - ABVD protocol
SB  - IM
MH  - Adult
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Bleomycin/therapeutic use
MH  - Combined Modality Therapy
MH  - Dacarbazine/therapeutic use
MH  - Doxorubicin/therapeutic use
MH  - Female
MH  - Fibronectins/*blood
MH  - Follow-Up Studies
MH  - Hodgkin Disease/*blood/drug therapy/*physiopathology/radiotherapy
MH  - Humans
MH  - Interleukin-6/*blood
MH  - Male
MH  - Mediastinal Neoplasms/*blood/drug therapy/*physiopathology/radiotherapy
MH  - Middle Aged
MH  - Respiratory Function Tests
MH  - Tumor Necrosis Factor-alpha/*analysis
MH  - Vinblastine/therapeutic use
EDAT- 2000/01/29 09:00
MHDA- 2000/02/26 09:00
CRDT- 2000/01/29 09:00
PHST- 2000/01/29 09:00 [pubmed]
PHST- 2000/02/26 09:00 [medline]
PHST- 2000/01/29 09:00 [entrez]
PST - ppublish
SO  - Anticancer Res. 1999 Sep-Oct;19(5C):4475-9.